{
  "docId": "019de070-5095-745c-b54c-b78e5ae1b904",
  "docSlug": "0dc8a543e5d2136d106b59f85712c2a9",
  "documentTitle": "Taysha | IPO Presentation Deck | 66 slides",
  "authorId": "taysha",
  "authorName": "Taysha Gene Therapies",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 66,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a table-like structure to define the parameters of a Phase 1/2 clinical trial.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-5095-745c-b54c-b78e5ae1b904/22",
  "deckHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904",
  "deckJsonHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904.json",
  "deckAnchorHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.05,
        "x": 0.9,
        "y": 0.02
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed5cd3af-a61d-4755-919f-04c9ca979582",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "table",
      "text": "Study design and duration: Open-label, single center, Phase 1/2 trial; Patients evaluated for ~one year, followed by longer-term extension. Patient cohort (n=4): Age younger than 1 (inclusive); Pathogenic confirmation of mutation in HEXA or HEXB gene; Patients not on ventilator support. Intervention: Single total dose of 5x10^14 vg of AAV9/HEXB-P2A-HEXA; Delivered intrathecally. Key clinical assessments: Safety and tolerability; Gross motor and fine motor milestones; Bayley score, CHOP-INTEND; Bulbar function/vocalization; Respiratory function; Seizure frequency/medications; QOL and caretaker burden assessments. Key biomarker assessments: Hex A enzyme in CSF and serum; GM2 accumulation in CSF; LDH/AST in CSF; MRI changes",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2818d858-b68d-430e-9d40-8c980c4cb809",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "TSHA-101 for the treatment of GM2 Gangliosidosis to enter clinic by end of 2020",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cdc4a61-f266-4484-818c-cc85fb31712b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 16,
      "beatId": "92c49c1c-860e-455e-833b-2b3bc63c64c4",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The deck presents the problem statements, context, and solution for various neurodegenerative and neurodevelopmental disorders, creating a desire for a solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 16,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "c5e05424-6f43-4bdf-8003-ce98529eabe9",
      "evidence": "The deck presents a logical chain of information, starting with the problem statement, then presenting context and solution.",
      "position": 0,
      "objective": "Understand the relationship between residual Hex A activity and the severity of GM2 gangliosidosis",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}